Researchers reported scalable methods for producing CAR‑engineered induced natural killer (CAR‑iNK) cells, advancing a route to off‑the‑shelf cellular immunotherapies. The work addresses manufacturing bottlenecks by demonstrating protocols for expansion, genetic modification and cryopreservation that preserve cytotoxicity and phenotype at scale. Investigators detail process parameters and quality attributes that enable larger‑batch runs and supply‑chain predictability compared with autologous CAR‑T products. The approach could reduce per‑patient costs and broaden access if clinical efficacy and safety are validated. Clarification: CAR‑iNK cells are NK‑cell based therapies genetically equipped with chimeric antigen receptors to target malignancies; they promise innate immunity benefits and potentially lower cytokine‑release risk than some CAR‑T platforms.